Bionik Laboratories (BNKL) 10-Q13 Nov 182019 Q2 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 13, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		2,337,964
Entity Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Current
Cash and cash equivalents	$ 305,757	$ 507,311
Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694)	517,758	212,730
Prepaid expenses and other receivables (Note 5)	851,179	433,655
Inventories (Note 6)	192,626	237,443
Due from related parties (Note 9(a))	18,913	18,897
Total Current Assets	1,886,233	1,410,036
Equipment (Note 7)	139,380	159,961
Technology and other assets (Note 4)	4,566,351	4,706,719
Goodwill	22,308,275	22,308,275
Total Assets	28,900,239	28,584,991
Current
Accounts payable (Notes 9(b) and 13)	906,438	724,673
Accrued liabilities (Note 9(b))	962,185	1,529,505
Customer advances	0	800
Demand loans (Note 8)	0	51,479
Deferred revenue	134,161	122,667
Shares to be issued, stock options and warrants (Notes 10, 11 and 12)	0	5,692,853
Total Current Liabilities	2,002,784	8,121,977
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized - 10,000,000; Special Voting Preferred Stock, par value $0.001 - Authorized, issued and outstanding - 1 (March 31, 2018 – 1)	0	0
Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 – 250,000,000); Issued and outstanding - 2,337,462 and 273,574 Exchangeable Shares (March 31, 2018 – 1,368,856 and 295,146 Exchangeable Shares)	2,611	1,664
Additional paid in capital	67,379,122	56,195,541
Deficit	(40,526,427)	(35,776,340)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders' Equity	26,897,455	20,463,014
Total Liabilities and Shareholders' Equity	$ 28,900,239	$ 28,584,991

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets [Parenthetical] - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Allowance for Doubtful Accounts Receivable, Current	$ 17,699	$ 19,694
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	250,000,000
Common Stock, Shares, Issued	2,337,462	1,368,856
Common Stock, Shares, Outstanding	2,337,462	1,368,856
Common Stock, Other Shares, Issued	273,574	295,146
Common Stock, Other Shares, Outstanding	273,574	295,146
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Sales	$ 547,085	$ 221,847	$ 1,048,418	$ 309,367
Cost of Sales	384,073	59,825	637,236	89,125
Gross Margin	163,012	162,022	411,182	220,242
Operating expenses
Sales and marketing	427,325	435,294	969,984	880,817
Research and development	679,049	715,400	1,355,792	1,401,309
General and administrative	931,477	1,505,528	1,910,956	2,133,134
Share-based compensation expense (Note 11)	439,328	762,208	1,034,740	1,013,256
Amortization (Note 4)	69,315	76,985	140,368	169,934
Depreciation (Note 7)	16,626	23,820	34,221	48,372
Total operating expenses	2,563,120	3,519,235	5,446,061	5,646,822
Other (income) expenses
Foreign exchange	(27,872)	15,595	(69,006)	114,156
Accretion expense (Note 8)	1,970,167	74,073	2,104,418	74,073
Fair value adjustment (Note 8)	(382,010)	0	(337,923)	0
Gain on mark to market revaluation (Note 10)	0	0	(2,048,697)	0
Other expense	22,712	168,480	60,132	241,068
Total other expenses (income)	1,582,997	258,148	(291,076)	429,297
Net loss and comprehensive loss for the period	$ (3,983,105)	$ (3,615,361)	$ (4,743,803)	$ (5,855,877)
Loss per share - basic and diluted	$ (1.62)	$ (5.33)	$ (2.02)	$ (8.84)
Loss per share - diluted	$ (1.62)	$ (5.33)	$ (2.02)	$ (8.84)
Weighted average number of shares outstanding – basic	2,459,169	678,631	2,351,587	662,237
Weighted average number of shares outstanding – diluted	2,459,169	678,631	2,351,587	662,237

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity - USD ($)	Total	Convertible Debt [Member]	Special Voting Preferred Stock [Member]	Total Shares [Member]	Total Shares [Member]Convertible Debt [Member]	Additional Paid in Capital [Member]	Additional Paid in Capital [Member]Convertible Debt [Member]	Shares to be issued [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Opening Balance at Mar. 31, 2017	$ 24,150,650		$ 0	$ 645		$ 45,184,320		$ 0	$ (21,076,464)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2017			1	645,297
Warrant exercised	1,125,038		$ 0	$ 34		1,125,004		0	0	0
Warrant exercised (in shares)			0	33,335
Share compensation expense	1,013,256		$ 0	$ 0		1,013,256		0	0	0
Share compensation expense (in shares)			0	0
Fair value of warrants on convertible loans	380,036		$ 0	$ 0		380,036		0	0	0
Warrant down round feature	0		0	0		41,025		0	(41,025)	0
Shares to be issued	60,000		$ 0	$ 0		0		60,000	0	0
Shares to be issued (in shares)			0	0
Net loss for the period	(5,855,877)		$ 0	$ 0		0		0	(5,855,877)	0
Closing Balance at Sep. 30, 2017	20,873,103		$ 0	$ 679		47,743,641		60,000	(26,973,366)	42,149
Closing Balance (in shares) at Sep. 30, 2017			1	678,632
Opening Balance at Mar. 31, 2017	24,150,650		$ 0	$ 645		45,184,320		0	(21,076,464)	42,149
Opening Balance (in shares) at Mar. 31, 2017			1	645,297
Warrant down round feature									(74,086)
Closing Balance at Mar. 31, 2018	20,463,014		$ 0	$ 1,664		56,195,541		0	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018			1	1,664,002
Opening Balance at Sep. 30, 2017	20,873,103		$ 0	$ 679		47,743,641		60,000	(26,973,366)	42,149
Opening Balance (in shares) at Sep. 30, 2017			1	678,632
Share compensation expense	527,324		$ 0	$ 0		527,324		0	0	0
Share compensation expense (in shares)			0	0
Fair value of warrants on convertible loans	168,143		$ 0	$ 0		168,143		0	0	0
Warrant down round feature	0		0	0		33,061		0	(33,061)	0
Shares to be issued for services	(60,000)		$ 0	$ 0				(60,000)	0	0
Shares to be issued for services (in shares)			0	0
Conversion of convertible notes	9,180,785		$ 0	$ 985		9,179,800		0	0	0
Conversion of convertible notes (in shares)			0	985,370
Stock option and warrant reclassification (Notes 11 & 12)	(2,845,557)		$ 0	$ 0		(2,845,557)		0	0	0
Beneficial conversion feature on convertible debt	1,389,129		0	0		1,389,129		0	0	0
Net loss for the period	(8,769,913)		0	0		0		0	(8,769,913)	0
Closing Balance at Mar. 31, 2018	20,463,014		$ 0	$ 1,664		56,195,541		0	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018			1	1,664,002
Share compensation expense	1,034,740		$ 0	$ 0		1,034,740		0	0	0
Share compensation expense (in shares)			0	0
Warrant down round feature	0		$ 0	$ 0		6,284		0	(6,284)	0
Conversion of convertible notes	2,470,622	$ 4,732,853	$ 0	$ 264	$ 683	2,470,358	$ 4,732,170	0	0	0
Conversion of convertible notes (in shares)			0	263,639	683,395
Fair value of Anti-dilution feature	1,766,495		$ 0	$ 0		1,766,495		0	0	0
Stock option and warrant reclassification (Notes 11 & 12)	1,173,534		0	0		1,173,534		0	0	0
Net loss for the period	(4,743,803)		0	0		0		0	(4,743,803)	0
Closing Balance at Sep. 30, 2018	$ 26,897,455		$ 0	$ 2,611		$ 67,379,122		$ 0	$ (40,526,427)	$ 42,149
Closing Balance (in shares) at Sep. 30, 2018			1	2,611,036

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities
Net loss for the period	$ (4,743,803)	$ (5,855,877)
Adjustment for items not affecting cash
Depreciation	34,221	48,372
Amortization	140,368	169,934
Interest expense	57,716	234,463
Share based compensation expense	1,034,740	1,013,256
Shares issued for services	0	60,000
Accretion expense	2,104,418	74,073
Fair value adjustment	(337,923)	0
Gain on mark to market revaluation	(2,048,697)	0
Allowance for doubtful accounts	(1,995)	(16,349)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(3,760,955)	(4,272,128)
Changes in non-cash working capital items
Accounts receivable	(303,033)	363,056
Prepaid expenses and other receivables	(417,524)	58,760
Due from related parties	(16)	(698)
Inventories	44,817	(3,193)
Accounts payable	181,765	172,634
Accrued liabilities	(567,320)	644,955
Customer advances	(800)	(12,462)
Deferred revenue	11,494	(10,773)
Net cash (used in) operating activities	(4,811,572)	(3,059,849)
Investing activities
Acquisition of equipment	(13,640)	(17,182)
Net cash (used in) investing activities	(13,640)	(17,182)
Financing activities
Proceeds from convertible loans	4,676,633	1,598,715
Proceeds on exercise of warrants	0	1,125,038
Repayment of Promissory notes principal	0	(12,319)
Repayment of Promissory notes interest	0	(41,973)
Repayment of Demand notes principal	(50,000)	0
Repayment of Demand notes interest	(2,975)	0
Net cash provided by financing activities	4,623,658	2,669,461
Net decrease in cash and cash equivalents for the period	(201,554)	(407,570)
Cash and cash equivalents, beginning of period	507,311	543,650
Cash and cash equivalents, end of period	$ 305,757	$ 136,080

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
NATURE OF OPERATIONS	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”), and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one share of its Special Voting Preferred Stock (Note 10). On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergeco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary which was renamed Bionik, Inc. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Inc., Bionik Acquisition Inc. and Bionik Canada. On November 6, 2017, the Company approved the authorization of a common share capital increase to 250,000,000 from 150,000,000 and on June 12, 2018, the Company approved the authorization of a common share capital increase to 500,000,000 from 250,000,000. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at September 30, 2018, the Company had a working capital deficit of $116,551 (March 31, 2018 – $6,711,941) and an accumulated deficit of $40,526,427 (March 31, 2018 – $35,766,340) and the Company incurred a net loss and comprehensive loss of $3,983,105 for the three month period ended September 30, 2018 (September 30, 2017 - $3,615,361) and $4,743,803 for the six month period ended September 30, 2018 (September 30, 2017 – $5,855,877). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due, however the Company believes it has the support of its major shareholders who have provided convertible loans to meet the Company’s cash flow needs and to continue as a going concern. The Company hopes to raise sufficient cash in the next six months to meet the Company’s anticipated cash requirements for the 12 months thereafter. Sales of additional equity or equity-linked securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, if these conditions are not achieved, this will raise significant doubt about the Company’s ability to continue as a going concern. The accompanying consolidated interim financial statements do not include any adjustments to reflect the possible effects of recoverability and reclassification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.

CHANGE IN ACCOUNTING POLICY AND

CHANGE IN ACCOUNTING POLICY AND CHANGE IN ACCOUNTING POLICY	6 Months Ended
CHANGE IN ACCOUNTING POLICY AND CHANGE IN ACCOUNTING POLICY	Sep. 30, 2018
Disclosure Text Block [Abstract]
Accounting Changes and Error Corrections [Text Block]	2. CHANGE IN ACCOUNTING POLICY AND CHANGE IN ACCOUNTING POLICY a) Basis of presentation On or about August 7, 2018, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of the Company s common stock and exchangeable shares at a ratio up to one-for-one hundred and fifty (1:150). On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split adjusted basis. As a result of The reverse stock split has no impact on the par value per share of Bionik’s common stock, which remains at $0.001. All current and prior period amounts related to share, share prices and earnings per share, warrant and options presented in the Company’s consolidated financial statements contained in this Quarterly report on Form 10-Q and the accompanying notes have been restated to give retrospective presentation for the reverse split. b) Change in accounting policy The FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): Accounting for Certain Financial Instruments With Down Round Features II Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception , allows a financial instrument with a down-round feature to no longer automatically be classified as a liability solely based on the existence of the down-round provision. The update also means the instrument would not have to be accounted for as a derivative and be subject to an updated fair value measurement each reporting period. On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company’s shares’ value changes. The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the second set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended September 30, 2018 are described below. Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements, which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s audited consolidated financial statements for the year ending March 31, 2019. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015- 17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 15, 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead. Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies and the impact on the unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods. Impact on the unaudited condensed consolidated interim financial statements ASU-2014-09 had no impact on the Company’s unaudited condensed consolidated interim statement of loss and comprehensive loss for the three and six month periods ended September 30, 2018. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $80,273 and $64,957 at September 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $5,208 and $15,316 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three and six month period ended September 30, 2018 (September 30, 2017 – $Nil and $Nil). Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates. Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended September 30, 2018.

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS	6 Months Ended
TECHNOLOGY AND OTHER ASSETS	Sep. 30, 2018
Technology And Other Intangible Assets [Abstract]
Intangible Assets Disclosure [Text Block]	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the six month period ended September 30, 2018 and the year ended March 31, 2018: Expense March Value at March Expense Sept. Value at Sept. Intangible Amortization Value acquired 31, 2018 31, 2018 30, 2018 30, 2018 assets acquired period (years) $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 1,045,530 67,045 978,485 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 71,584 1,081,959 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 140,368 4,566,351 Amortization for the six months ended September 30, 2017 was $169,934. Amortization for three months ended was $ ( - $

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	6 Months Ended
PREPAID EXPENSES AND OTHER RECEIVABLES	Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	5. PREPAID EXPENSES AND OTHER RECEIVABLES September 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 58,694 86,957 Prepaid inventory 672,231 301,104 Prepaid insurance 103,070 36,497 Sales taxes receivable (i) 17,184 9,097 851,179 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	6 Months Ended
INVENTORIES	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. INVENTORIES September 30, 2018 March 31, 2018 $ $ Raw materials 87,006 237,443 Finished goods 105,620 - 192,626 237,443 During the three and six month periods ended September 30, 2018, the Company expensed $342,345 and $579,354, in inventory as cost of goods sold (September 30, 2017 – $58,600 and $87,900).

EQUIPMENT

EQUIPMENT	6 Months Ended
EQUIPMENT	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. EQUIPMENT Equipment consisted of the following as at September 30, 2018 and March 31, 2018: September 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 270,145 232,639 37,506 256,505 223,750 32,755 Furniture and fixtures 36,795 28,889 7,906 36,795 28,051 8,744 Demonstration equipment 200,186 126,793 73,393 200,186 105,441 94,745 Manufacturing equipment 88,742 85,963 2,779 88,742 85,668 3,074 Tools and parts 11,422 6,286 5,136 11,422 5,741 5,681 Assets under capital lease 23,019 10,359 12,660 23,019 8,057 14,962 630,309 490,929 139,380 616,669 456,708 159,961 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three and six month periods ended September 30, 2018 was $16,626 and $34,221, respectively (September 30, 2017 – $23,820 and $ 48,372

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
NOTES PAYABLE	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. NOTES PAYABLE Demand Notes payable The Company had outstanding notes payable (“Notes”) of $Nil at September 30, 2018 ($51,479 – March 31, 2018) which was acquired when the Company bought IMT on April 21, 2016. The Notes and interest were repaid during the Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment (52,975 ) Balance, September 30, 2018 $ - Interest expense incurred on the Notes totaled $1,496 for the three and six month periods ended September 30, 2018 (September 30, 2017 – $5,251 and $9,898), which was included in accrued liabilities until it was paid off. Convertible Loans Payable During the six month period ended September 30, 2018, the Company received loans totaling $4,708,306 (which is inclusive of $31,673 that was capitalized interest) which carry an interest rate of 1% per month and of which $2,297,928 came from related parties. The loans and interest thereon were converted as of July 20, 2018 at a 10% discount to the 30 day volume weighted In the event the Company consummates a firm commitment or underwritten offering of its common stock by March 27, 2019, and the price per share thereof (the “ Offering Price ”) is less than the original conversion price on July 20, 2018, then in such event the Company shall issue to all convertible loan holder at June 30, 2018, at no further cost, additional shares of common stock equal to the number of conversion shares the shareholders that they would have received upon conversion if the conversion price equaled the Offering Price, less the number of shares of conversion shares actually issued on July 20, 2018. The tables below reflect the fair value and anti-dilution features of the convertible loans, which resulted in accretion expense for the three and six months ended September 30, 2018 of $1,970,167 and $2,104,418 and a fair value adjustment of $382,010 and $337,923 being expensed for the three and six month ended September 30, 2018 (September 30, 2017 - $74,073 accretion for both periods and $Nil and $Nil fair value adjustment). At issuance At July 20, 2018 Conversion feature fair value Principal Beneficial conversion Anti-dilution Fair value of debt Accretion expense Interest Loan converted Convertible promissory note $ 4,708,306 $ 406,744 $ 1,697,674 $ 2,603,888 $ 2,104,418 $ 24,547 $ 4,732,853 Conversion feature fair value Beneficial conversion Anti-dilution Total At Issuance $ 406,744 $ 1,697,674 $ 2,104,418 Fair value adjustment $ (406,744 ) $ 68,821 $ (337,923 ) Balance allocated to equity on conversion $ - $ (1,766,495 ) $ (1,766,495 ) Ending balance at September 30, 2018 $ - $ - $ -

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	6 Months Ended
RELATED PARTY TRANSACTIONS AND BALANCES	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. RELATED PARTY TRANSACTIONS AND BALANCES a) Due from related parties As at September 30, 2018, there was an outstanding loan to the Chief Technology Officer of the Company for $18,913 (March 31, 2018 – $18,897). The loan has an interest rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the six month period ended September 30, 2018, the Company accrued interest receivable in the amount of $91 (March 31, 2018 – $707) and the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. b) Accounts payable and accrued liabilities As at September 30, 2018, $24,489 (March 31, 2018 – $208,567) was owing to the CEO of the Company; $1,985 (March 31, 2018 – $135,039) was owing to the Chief Technology Officer; and $1,215 (March 31, 2018 – $116,624) was owing to the Chief Financial Officer, all related to business expenses. Balances owing are included in accounts payable or accrued liabilities.

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended
SHARE CAPITAL	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. SHARE CAPITAL September 30, 2018 March 31, 2018 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of year 295,146 295 319,396 319 Converted into common shares (a) (21,572 ) (22 ) (24,250 ) (24 ) Balance at the end of period 273,574 273 295,146 295 Common Shares Balance at beginning of the period 1,368,856 1,369 325,901 326 Shares issued to exchangeable shares 21,572 22 24,250 24 Shares issued on conversion of loans (b) 947,034 947 985,370 986 Warrants exercised - - 33,335 33 Balance at end of the period 2,337,462 2,338 1,368,856 1,369 TOTAL SHARES 2,611,036 2,611 1,664,002 1,664 (a) During the six month period ended September 30, 2018 21,572 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250) (b) During the six month period ended September 30, 2018, 947,034 shares of common stock were issued. Of this amount 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. The Company converted $4,732,853 of convertible loans and interest into 683,395 common shares on July 20, 2018 in accordance with their terms. (c) On October 29, 2018 the Company completed the consolidation on a one-for-one to one hundred and fifty (1:150) reverse consolidation. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value $ 0.001 In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

STOCK OPTIONS

STOCK OPTIONS	6 Months Ended
STOCK OPTIONS	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company granted 4,334 options granted to employees at an exercise price of $183.00 per share that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 1,667 options were cancelled and during the three and six month period ended September 30, 2018, $35,609 and $71,219 (September 30, 2017 – $35,609 and $71,218) in stock compensation expense was recognized. On December 14, 2015, the Company granted 16,634 options to employees, directors and consultants at an exercise price of $150 per share that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the years ended March 31, 2016, 2017 and 2018 and for the six month period ended September 30, 2018, 167 options, 267 options, 2,912 options and 789 options, respectively, were cancelled and for the three and six month period ended September 30, 2018, $36,275 and $77,625 (September 30, 2017 – $298,573 and $396,523) of stock compensation expense was recognized. On April 21, 2016, the Company granted 20,000 stock options to employees of Bionik, Inc., the Company’s wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT of which 6,667 have an exercise price $37.50 per share, 6,667 have an exercise price of $142.50 per share and 16,666 have an exercise price of $157.50 per share. The grant date fair value of vested options was $2,582,890 and has been recorded as part of the original acquisition equation. The options are fully expensed. On April 26, 2016, the Company granted 1,667 options to an employee with an exercise price of $150 per share that vest over three years at the anniversary date. The grant fair value was $213,750. During the three and six months ended September 30, 2018, $17,813 and $35,625 (September 30, 2017- $17,813 and $35,625) was recognized as stock compensation expense. On August 8, 2016, the Company granted 5,000 options to an employee with an exercise price of $150 per share that vest over three years at the anniversary date. The grant fair value was $652,068. The employee left in April 2018 and 3,334 options that had not vested were cancelled and the remaining 1,667 options will expire in November 2018. During the three and six months ended September 30, 2018, $18,113 and $36,226 (September 30, 2017 – $54,339 and $108,678) of stock compensation expense was recognized. On February 6, 2017, the Company granted 2,667 options to an employee with an exercise price of $105.00 per share that vest over three years at the anniversary date. The grant fair value was $245,200. During the three and six months ended September 30, 2018, $20,433 and $40,867 (September 30, 2017 – $20,433 and $40,867) of stock compensation expense was recognized. On February 13, 2017, the Company granted 1,667 options to a consultant with an exercise price of $102.00 per share that vest over one and one-half years, every six months. The grant fair value was $148,750. During the three and six months ended September 30, 2018, $80,425 and $92,821 (September 30, 2017 – $12,396 and $24,792) of stock compensation expense was recognized. These options are now fully vested. On August 3, 2017, 10,000 options with an exercise price of $31.50 per share were granted to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 13,334 additional performance options based on meeting sales targets for the years ended March 31, 2018 and 2019. The grant value was $387,209 and $7,546 e executive left in April 2018 and all of these options were cancelled. On September 1, 2017, the Company granted % of the remaining options vest on performance goals being met and % vest over years, the remaining options vest over 5 years. The grant fair value was $1,832,304 and for the three and six months ended September 30, 2018, $190,865 and $229,037 in stock compensation expense was recognized. On January 24, 2018, the Company granted 24,267 options with an exercise price of $ 23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021, The grant fair value was $ 491,036 . During the six month period ended September 30, 2018, 2,834 options were cancelled and for the three and six months ended September 30, 2018, $ 37,266 and $ 76,968 in stock compensation expense was recognized. On April 20, 2018, the Company granted to an executive officer, 40,000 options with an exercise price of $ 9.74 per share that vest immediately with a 10 -year expiry. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 10 years, expected volatility of 114 % and a risk free rate of 1.59 %. As these options fully vested on the grant date, $ 363,714 of stock based compensation was recognized On June 11, 2018, the Company granted to a newly-hired executive officer 5,000 options with an exercise price of $ 6.93 per share that vest over three years from the anniversary of the grant and expire in 7 years. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114 % and a risk free rate of 1.59 %. The grant fair value was $ 30,341 , and $ 2,528 and $ 3,090 of stock compensation expense was recognized in the three and six months ended September 30, 2018 During the three and six months ended September 30, 2018, the Company recorded $ 439,328 and $ 1,034,740 in share-based compensation related to the vesting of stock options (September 30, 2017 – $ 762,208 and $ 1,013,256) . The following is a summary of stock options outstanding and exercisable as of September 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,028 April 1, 2021 1,028 34.50 630 June 20, 2021 630 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 12,912 December 14, 2022 10,889 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 1,112 150.00 1,667 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,667 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14,2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 24 June 2, 2025 24 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 24.15 81,436 September 1, 2027 20,360 23.25 22,434 January 24, 2025 - 9.735 40,000 April 19, 2028 40,000 6.93 5,000 June 10, 2025 - 196,044 102,143 The weighted-average remaining contractual term of the outstanding options was 7.53 (March 31, 2018 – 5.81) and for the options that are exercisable the weighted average was 7.15 (March 31, 2018 – 5.70) .

WARRANTS

WARRANTS	6 Months Ended
WARRANTS	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected to warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected to warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with the conversion of loans and interest into common shares 106,709 9.375 Issued in connection with the conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected to warrant transaction 136,388 73.02 Issued in connection with anti-dilution provision connected to warrant transaction 13,464 44.28 Outstanding at March 31, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected to warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected to warrant transaction 6,305 34.50 Outstanding at September 30, 2018 440,231 44.21 During the year ended March 31, 2018, the Company consummated an offer to amend and exercise its outstanding warrants, enabling the holders of the warrants to exercise such warrants for $37.50 per share. The Company received net proceeds of $1,125,038. The Company also converted loans and interest due. Due to the anti-dilution clause in the warrant agreement for such outstanding warrants, an additional 559 the $120 per share warrants and an additional 6,275 $210.00 per share warrants. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants were adjusted from $120.00 per share to $112.35 per share and from $210.00 per share to $194.00 per share. Due to the anti-dilution clause in the warrant agreements for such outstanding warrants, an additional 13,464 the $112.35 per share warrant and an additional 136,388 the $194.00 per share warrants. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants from $112.50 per share to $44.28 per share and from $194.00 per share to $73.02 per share, all as a result of the loan and interest conversion for shares at March 31, 2018 and June 12, 2018. The Company measured the effects of the above two transactions, which triggered anti-dilution clause using the binomial tree model and recorded a loss of $74,086 against the deficit for the year ended March 31, 2018. The Company issued 2,667 warrants at $37.50 per share for four years expiring June 27, 2020 to the firm who facilitated the warrant offer. The Company issued 15,658 warrants at $90.00 per share which expire in 5 years on March 31, 2023 and 106,709 warrants at $9.375 per share which also expire March 31, 2023 in connection with the loan and interest conversion transaction. Due to the anti-dilution clause in the warrant agreements for such outstanding warrants, the warrants were adjusted to reflect an additional 67,952 shares underlying the $73.02 per share warrants and an additional 6,305 shares underlying the $44.28 per share warrants. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants were adjusted from $73.02 per share to $55.71 per share and from $44.28 per share to $34.50 per share, all as a result of a loan and interest conversion for shares on July 20, 2018. Common share purchase warrants The following is a summary of common share purchase warrants as of September 30, 2018: Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 55.71 136,339 February 26, 2019 55.71 28,531 March 27, 2019 55.71 7,618 March 31, 2019 55.71 59,061 April 21, 2019 55.71 27,883 May 27,2019 55.71 27,238 June 30, 2019 34.50 28,527 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 440,231 The weighted-average remaining contractual term of the outstanding warrants was 1.53 (March 31, 2018 – 2.27). The exercise price and number of underlying shares of the Company’s outstanding warrants currently priced at $ 55.71 34.50

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain, and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments a. On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the former Chief Technology Officer and the new Chief Technology Officer had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former Chief Technology Officer and the new Chief Technology Officer 2,134 common shares collectively. As at 30, 2018, these shares have not yet been issued. b. In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1% of sales based on patent #8,613,691. No sales were made on the technology under this patent as it has not yet been commercialized. One of the licensors is a founder of IMT and a former officer and director of the Company. c. On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at September 30, 2018. d. On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form a China-based joint venture to commercialize the Company’s products (“China JV”) in which the Company has a 25% interest and the JV Partner has a 75% interest.

RISK MANAGEMENT

RISK MANAGEMENT	6 Months Ended
RISK MANAGEMENT	Sep. 30, 2018
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT The Company’s cash balances are maintained in a bank in Canada and a USA bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. SUBSEQUENT EVENTS (a) Subsequent to September 30, 2018, investors, including a company controlled by the Company’s Chairman, loaned an aggregate of $2,750,000 to the Company, evidenced by convertible promissory notes. The convertible promissory notes bear interest at a fixed rate of 1% per month and are convertible based on a 20% discount to the 30 day VWAP of the Company’s stock price if more than $2,000,000 is raised in an equity financing or upon maturity on March 28, 2019. (b) On October 29, 2018, the Company completed a reverse stock split and thereafter the Company’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. Refer to details in Note 2(a).

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2018
Accounting Policies [Abstract]
Consolidated Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the second set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended September 30, 2018 are described below.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements, which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s audited consolidated financial statements for the year ending March 31, 2019. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015- 17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 15, 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies and the impact on the unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $80,273 and $64,957 at September 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $5,208 and $15,316 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three and six month period ended September 30, 2018 (September 30, 2017 – $Nil and $Nil).
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended September 30, 2018.

TECHNOLOGY AND OTHER ASSETS (Ta

TECHNOLOGY AND OTHER ASSETS (Tables)	6 Months Ended
TECHNOLOGY AND OTHER ASSETS (Tables)	Sep. 30, 2018
Technology And Other Intangible Assets [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the six month period ended September 30, 2018 and the year ended March 31, 2018: Expense March Value at March Expense Sept. Value at Sept. Intangible Amortization Value acquired 31, 2018 31, 2018 30, 2018 30, 2018 assets acquired period (years) $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 1,045,530 67,045 978,485 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 71,584 1,081,959 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 140,368 4,566,351

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	6 Months Ended
PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 58,694 86,957 Prepaid inventory 672,231 301,104 Prepaid insurance 103,070 36,497 Sales taxes receivable (i) 17,184 9,097 851,179 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
INVENTORIES (Tables)	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	September 30, 2018 March 31, 2018 $ $ Raw materials 87,006 237,443 Finished goods 105,620 - 192,626 237,443

EQUIPMENT (Tables)

EQUIPMENT (Tables)	6 Months Ended
EQUIPMENT (Tables)	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at September 30, 2018 and March 31, 2018: September 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 270,145 232,639 37,506 256,505 223,750 32,755 Furniture and fixtures 36,795 28,889 7,906 36,795 28,051 8,744 Demonstration equipment 200,186 126,793 73,393 200,186 105,441 94,745 Manufacturing equipment 88,742 85,963 2,779 88,742 85,668 3,074 Tools and parts 11,422 6,286 5,136 11,422 5,741 5,681 Assets under capital lease 23,019 10,359 12,660 23,019 8,057 14,962 630,309 490,929 139,380 616,669 456,708 159,961

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
NOTES PAYABLE (Tables)	Sep. 30, 2018
Convertible Debt [Table Text Block]	Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment (52,975 ) Balance, September 30, 2018 $ -
Schedule of Convertible Debt Fair Value [Table Text Block]	At issuance At July 20, 2018 Conversion feature fair value Principal Beneficial conversion Anti-dilution Fair value of debt Accretion expense Interest Loan converted Convertible promissory note $ 4,708,306 $ 406,744 $ 1,697,674 $ 2,603,888 $ 2,104,418 $ 24,547 $ 4,732,853
Schedule of Convertible Debt Beneficial Conversion Feature Table text Block [Table Text Block]	Conversion feature fair value Beneficial conversion Anti-dilution Total At Issuance $ 406,744 $ 1,697,674 $ 2,104,418 Fair value adjustment $ (406,744 ) $ 68,821 $ (337,923 ) Balance allocated to equity on conversion $ - $ (1,766,495 ) $ (1,766,495 ) Ending balance at September 30, 2018 $ - $ - $ -

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	6 Months Ended
SHARE CAPITAL (Tables)	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	September 30, 2018 March 31, 2018 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of year 295,146 295 319,396 319 Converted into common shares (a) (21,572 ) (22 ) (24,250 ) (24 ) Balance at the end of period 273,574 273 295,146 295 Common Shares Balance at beginning of the period 1,368,856 1,369 325,901 326 Shares issued to exchangeable shares 21,572 22 24,250 24 Shares issued on conversion of loans (b) 947,034 947 985,370 986 Warrants exercised - - 33,335 33 Balance at end of the period 2,337,462 2,338 1,368,856 1,369 TOTAL SHARES 2,611,036 2,611 1,664,002 1,664 (a) During the six month period ended September 30, 2018 21,572 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250) (b) During the six month period ended September 30, 2018, 947,034 shares of common stock were issued. Of this amount 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. The Company converted $4,732,853 of convertible loans and interest into 683,395 common shares on July 20, 2018 in accordance with their terms. (c) On October 29, 2018 the Company completed the consolidation on a one-for-one to one hundred and fifty (1:150) reverse consolidation.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	6 Months Ended
STOCK OPTIONS (Tables)	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of September 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 24.75 1,028 April 1, 2021 1,028 34.50 630 June 20, 2021 630 34.50 13,212 July 1, 2021 13,212 34.50 944 February 17, 2022 944 183.00 2,667 November 24, 2022 1,778 150.00 12,912 December 14, 2022 10,889 142.50 747 March 28, 2023 747 157.50 2,887 March 28, 2023 2,887 150.00 1,667 April 26, 2023 1,112 150.00 1,667 August 8, 2023 1,667 105.00 2,667 February 6, 2024 889 102.00 1,667 February 13, 2024 1,667 142.50 211 March 3, 2024 211 157.50 816 March 3, 2024 816 142.50 43 March 14, 2024 43 157.50 164 March 14,2024 164 142.50 485 September 30, 2024 485 157.50 1,876 September 30, 2024 1,876 142.50 24 June 2, 2025 24 157.50 90 June 2, 2025 90 37.50 442 December 30, 2025 442 142.50 328 December 30, 2025 182 24.15 81,436 September 1, 2027 20,360 23.25 22,434 January 24, 2025 - 9.735 40,000 April 19, 2028 40,000 6.93 5,000 June 10, 2025 - 196,044 102,143

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
WARRANTS (Tables)	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted-Average Number of Warrants Exercise Price ($) Outstanding and exercisable, March 31, 2015 72,157 202.50 Issued 48,171 202.50 Exercised (992 ) (120.00 ) Outstanding and exercisable, March 31, 2016 119,336 202.50 Exercised (1,747 ) (120.00 ) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected to warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected to warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with the conversion of loans and interest into common shares 106,709 9.375 Issued in connection with the conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected to warrant transaction 136,388 73.02 Issued in connection with anti-dilution provision connected to warrant transaction 13,464 44.28 Outstanding at March 31, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected to warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected to warrant transaction 6,305 34.50 Outstanding at September 30, 2018 440,231 44.21
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants as of September 30, 2018: Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 55.71 136,339 February 26, 2019 55.71 28,531 March 27, 2019 55.71 7,618 March 31, 2019 55.71 59,061 April 21, 2019 55.71 27,883 May 27,2019 55.71 27,238 June 30, 2019 34.50 28,527 February 26, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 440,231

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

Oct. 29, 2018

Apr. 21, 2016

Feb. 26, 2015

Feb. 13, 2015

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Jun. 12, 2018

Mar. 31, 2018

Nov. 06, 2017

Mar. 31, 2017

Dec. 31, 2014

Working Capital Surplus (Deficit)

$ 116,551

$ 6,711,941

Comprehensive Income (Loss), Net of Tax

$ (3,983,105)

$ (3,615,361)

$ (4,743,803)

$ (5,855,877)

Common Stock, Shares Authorized

500,000,000

250,000,000

150,000,000

200,000,000

Retained Earnings (Accumulated Deficit)

$ (40,526,427)

$ (35,776,340)

Stockholders' Equity, Reverse Stock Split

the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.

Subsequent Event [Member]

Stockholders' Equity, Reverse Stock Split

the Company effected a reverse stock split and thereafter Bionik's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split adjusted basis.

Interactive Motion Technologies, Inc. [Member]

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

157,667

Share Exchange Agreement [Member]

Stock Issued During Period, Shares, New Issues

333,334

Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage

100.00%

CHANGE IN ACCOUNTING POLICY A_2

CHANGE IN ACCOUNTING POLICY AND CHANGE IN ACCOUNTING POLICY (Details Textual) - $ / shares	1 Months Ended
	Oct. 29, 2018	Aug. 07, 2018	Feb. 13, 2015	Sep. 30, 2018	Mar. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Common Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001
Stockholders' Equity, Reverse Stock Split			the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.
Approved Reverse Stock Split [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Reverse Stock Split		reverse stock split of Bionik's common and exchangeable shares at a ratio up to one-for-one hundred and fifty (1:150).
Subsequent Event [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' Equity, Reverse Stock Split	the Company effected a reverse stock split and thereafter Bionik's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split adjusted basis.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 12, 2018	Mar. 31, 2018	Nov. 06, 2017	Mar. 31, 2017	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 80,273		$ 80,273			$ 64,957
Product Warranty Expense	$ 5,208	$ 0	$ 15,316	$ 0
Common Stock, Shares Authorized	500,000,000		500,000,000		500,000,000	250,000,000	250,000,000	150,000,000	200,000,000
Loss on Mark to Market Reevaluation			$ (2,048,697)	$ 0

TECHNOLOGY AND OTHER ASSETS (De

TECHNOLOGY AND OTHER ASSETS (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
TECHNOLOGY AND OTHER ASSETS (Details) - USD ($)	Apr. 21, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets		$ 69,315	$ 76,985	$ 140,368	$ 169,934	$ 323,905
Intangible Assets, Net (Excluding Goodwill)		4,566,351		4,566,351		4,706,719
Patents and exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Amortization of Intangible Assets				67,045		134,126
Intangible Assets, Net (Excluding Goodwill)		978,485		978,485		1,045,530
Trademark [Member]
Finite Lived Intangible Asset Useful Life Description	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Amortization of Intangible Assets				0		0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		2,505,907		2,505,907
Customer relationships [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Amortization of Intangible Assets				71,584		143,206
Intangible Assets, Net (Excluding Goodwill)		1,081,959		1,081,959		1,153,543
Non compete agreement [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets				1,739		30,709
Intangible Assets, Net (Excluding Goodwill)		0		0		1,739
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets				0		15,864
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 0		$ 0

TECHNOLOGY AND OTHER ASSETS (_2

TECHNOLOGY AND OTHER ASSETS (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
TECHNOLOGY AND OTHER ASSETS (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018
Amortization of Intangible Assets	$ 69,315	$ 76,985	$ 140,368	$ 169,934	$ 323,905

PREPAID EXPENSES AND OTHER RE_3

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Sep. 30, 2018	Mar. 31, 2018
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 58,694	$ 86,957
Prepaid inventory		672,231	301,104
Prepaid insurance		103,070	36,497
Sales taxes receivable	[1]	17,184	9,097
Prepaid Expense and Other Receivables		$ 851,179	$ 433,655

[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Inventory [Line Items]
Raw materials	$ 87,006	$ 237,443
Finished goods	105,620	0
Inventory, Net	$ 192,626	$ 237,443

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
INVENTORIES (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cost of Goods and Services Sold	$ 384,073	$ 59,825	$ 637,236	$ 89,125
Inventory Cost [Member]
Cost of Goods and Services Sold	$ 342,345	$ 58,600	$ 579,354	$ 87,900

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Equipment [Line Items]
Equipment, Cost	$ 630,309	$ 616,669
Accumulated Depreciation	490,929	456,708
Equipment, Net	139,380	159,961
Computers and electronics [Member]
Equipment [Line Items]
Equipment, Cost	270,145	256,505
Accumulated Depreciation	232,639	223,750
Equipment, Net	37,506	32,755
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	28,889	28,051
Equipment, Net	7,906	8,744
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	200,186	200,186
Accumulated Depreciation	126,793	105,441
Equipment, Net	73,393	94,745
Manufacturing equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	85,963	85,668
Equipment, Net	2,779	3,074
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	6,286	5,741
Equipment, Net	5,136	5,681
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	10,359	8,057
Equipment, Net	$ 12,660	$ 14,962

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
EQUIPMENT (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Equipment [Line Items]
Depreciation	$ 16,626	$ 23,820	$ 34,221	$ 48,372

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	6 Months Ended
NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Repayment	$ 0	$ (12,319)
Demand Notes payable [Member]
Balance, March 31, 2018	51,479
Accrued interest	1,496
Repayment	(52,975)
Balance, September 30, 2018	$ 0

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
NOTES PAYABLE (Details 1) - USD ($)	Jul. 20, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Beneficial conversion
Anti-dilution
Accretion expense		1,970,167	$ 74,073	$ 2,104,418	$ 74,073
Convertible Debt [Member]
Principal		4,708,306		4,708,306
Beneficial conversion				406,744
Anti-dilution				1,697,674
Fair value of debt		2,603,888		2,603,888
Accretion expense	$ 2,104,418
Fair value adjustment		$ 382,010	$ 0	$ 337,923	$ 0
Interest	24,547
Loan converted	$ 4,732,853

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) - Convertible Debt [Member]	6 Months Ended
NOTES PAYABLE (Details 2) - Convertible Debt [Member]	Sep. 30, 2018USD ($)
At Issuance	$ 2,104,418
Fair value adjustment	(337,923)
Balance allocated to equity on conversion	(1,766,495)
Ending balance at September 30, 2018	0
Beneficial conversion [Member]
At Issuance	406,744
Fair value adjustment	(406,744)
Balance allocated to equity on conversion	0
Ending balance at September 30, 2018	0
Anti-dilution [Member]
At Issuance	1,697,674
Fair value adjustment	68,821
Balance allocated to equity on conversion	(1,766,495)
Ending balance at September 30, 2018	$ 0

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
NOTES PAYABLE (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jul. 20, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Short-term Debt	$ 0		$ 0			$ 51,479
Accretion Expense	$ 1,970,167	$ 74,073	$ 2,104,418	$ 74,073
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%		1.00%
Proceeds from Related Party Debt			$ 2,297,928
Proceeds from Convertible Debt Including Capitalized Interest			4,708,306
Discount on Convertible Loan exercise price					10.00%
Interest Costs Capitalized			31,673
Accretion Expense	$ 1,970,167	74,073	2,104,418	74,073
Demand Notes payable [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	$ 1,496	$ 5,251	$ 1,496	$ 9,898

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Related Party Transaction [Line Items]
Accrued interest receivable	$ 91	$ 707
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	24,489	208,567
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	18,913	18,897
Accounts Payable, Related Parties	$ 1,985	135,039
Related Party Transaction, Rate	1.00%
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 1,215	$ 116,624

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		1 Months Ended	6 Months Ended			12 Months Ended
SHARE CAPITAL (Details) - USD ($)		Jul. 20, 2018	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2018
Opening Balance			$ 20,463,014	$ 20,873,103	$ 24,150,650	$ 24,150,650
Shares issued to exchangeable shares		$ 4,732,853	2,470,622	9,180,785
Warrants exercised					1,125,038
Closing Balance			$ 26,897,455	$ 20,463,014	$ 20,873,103	$ 20,463,014
Exchangable Shares [Member]
Opening Balance (in shares)			295,146		319,396	319,396
Opening Balance			$ 295		$ 319	$ 319
Converted into common shares (in shares)	[1]		(21,572)			(24,250)
Converted into common shares	[1]		$ (22)			$ (24)
Closing Balance (in shares)			273,574	295,146		295,146
Closing Balance			$ 273	$ 295		$ 295
Common Shares [Member]
Opening Balance (in shares)			1,368,856		325,901	325,901
Opening Balance			$ 1,369		$ 326	$ 326
Shares issued to exchangeable shares (in shares)			21,572			24,250
Shares issued to exchangeable shares			$ 22			$ 24
Shares issued on conversion of loans (in shares)	[2]		947,034			985,370
Shares issued on conversion of loans	[2]		$ 947			$ 986
Warrants exercised (in shares)			0			33,335
Warrants exercised			$ 0			$ 33
Closing Balance (in shares)			2,337,462	1,368,856		1,368,856
Closing Balance			$ 2,338	$ 1,369		$ 1,369
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)			1,664,002
Opening Balance			$ 1,664
Closing Balance (in shares)			2,611,036	1,664,002		1,664,002
Closing Balance			$ 2,611	$ 1,664		$ 1,664

[1]	During the six month period ended September 30, 2018 21,572 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250)
[2]	During the six month period ended September 30, 2018, 947,034 shares of common stock were issued. Of this amount 263,639 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. The Company converted $4,732,853 of convertible loans and interest into 683,395 common shares on July 20, 2018 in accordance with their terms.,

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)

1 Months Ended

6 Months Ended

12 Months Ended

Oct. 29, 2018

Jul. 20, 2018

Feb. 26, 2015

Feb. 13, 2015

Sep. 30, 2018

Mar. 31, 2018

Sep. 30, 2017

Mar. 31, 2018

Jun. 12, 2018

Nov. 06, 2017

Mar. 31, 2017

Dec. 31, 2014

Debt Conversion, Original Debt, Amount

$ 4,732,853

Loss on Mark to Market Reevaluation

$ (2,048,697)

$ 0

Stock Issued During Period, Shares, Exchangeable Shares Excercised

21,572

24,250

Common Stock, Shares Authorized

500,000,000

250,000,000

500,000,000

250,000,000

150,000,000

200,000,000

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 4,732,853

$ 2,470,622

$ 9,180,785

Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification

$ 1,173,534

$ (2,845,557)

Preferred Stock, Voting Rights

the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share

Stockholders' Equity, Reverse Stock Split

the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.

Common Shares [Member]

Stock Issued During Period, Shares, Conversion of Convertible Securities

947,034

Subsequent Event [Member]

Stockholders' Equity, Reverse Stock Split

the Company effected a reverse stock split and thereafter Bionik's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split adjusted basis.

Convertible Debt [Member]

Stock Issued During Period, Shares, Conversion of Convertible Securities

683,395

Convertible Debt [Member] | Common Shares [Member]

Stock Issued During Period, Shares, Conversion of Convertible Securities

263,639

STOCK OPTIONS (Details)

STOCK OPTIONS (Details)	6 Months Ended
STOCK OPTIONS (Details)	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	196,044
Number of Exercisable Options	102,143
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 24.75
Number of Options	1,028
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	1,028
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 34.50
Number of Options	630
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	630
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 34.50
Number of Options	13,212
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	13,212
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 34.50
Number of Options	944
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	944
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 183
Number of Options	2,667
Expiry Date	Nov. 24, 2022
Number of Exercisable Options	1,778
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 150
Number of Options	12,912
Expiry Date	Dec. 14, 2022
Number of Exercisable Options	10,889
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	747
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	747
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 157.50
Number of Options	2,887
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	2,887
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 150
Number of Options	1,667
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	1,112
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 150
Number of Options	1,667
Expiry Date	Aug. 8, 2023
Number of Exercisable Options	1,667
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 105
Number of Options	2,667
Expiry Date	Feb. 6, 2024
Number of Exercisable Options	889
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 102
Number of Options	1,667
Expiry Date	Feb. 13, 2024
Number of Exercisable Options	1,667
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	211
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	211
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 157.50
Number of Options	816
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	816
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	43
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	43
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 157.50
Number of Options	164
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	164
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	485
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	485
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 157.50
Number of Options	1,876
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	1,876
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	24
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	24
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 157.50
Number of Options	90
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	90
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 37.50
Number of Options	442
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	442
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 142.50
Number of Options	328
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	182
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 24.15
Number of Options	81,436
Expiry Date	Sep. 1, 2027
Number of Exercisable Options	20,360
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 23.25
Number of Options	22,434
Expiry Date	Jan. 24, 2025
Number of Exercisable Options	0
Stock Option Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 9.735
Number of Options	40,000
Expiry Date	Apr. 19, 2028
Number of Exercisable Options	40,000
Stock Option Twenty Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 6.93
Number of Options	5,000
Expiry Date	Jun. 10, 2025
Number of Exercisable Options	0

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)	Jun. 11, 2018	Sep. 01, 2017	Feb. 06, 2017	Dec. 14, 2015	Aug. 08, 2018	Apr. 30, 2018	Apr. 20, 2018	Jan. 24, 2018	Aug. 03, 2017	Feb. 13, 2017	Apr. 26, 2016	Apr. 21, 2016	Nov. 24, 2015	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								24,267
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 23.25				$ 142.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																	2,834				1,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number														196,044			196,044
Allocated Share-based Compensation Expense														$ 37,266			$ 76,968
Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value												$ 2,582,890
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															0 years		7 years 6 months 11 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term															0 years		7 years 1 month 24 days
Fair Value Of Options			$ 245,200
Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period												6,667
Exercise Price Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period												6,667
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense														439,328		$ 762,208	$ 1,034,740	$ 1,013,256
Employees of Bionik Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												20,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 150	$ 157.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period											1,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number												3,895,000
Allocated Share-based Compensation Expense														17,813		17,813	35,625	35,625
Fair Value Of Options											$ 213,750
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period												16,666
Employees of Bionik Inc [Member] \| Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price												$ 37.50
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross													4,334
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price													$ 183
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period													1,667
Allocated Share-based Compensation Expense														35,609		35,609	71,219	71,218
Fair Value Of Options								$ 491,036					$ 694,384
Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					5,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						3,334
Allocated Share-based Compensation Expense														18,113		54,339	$ 36,226	108,678
Fair Value Of Options					$ 652,068
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period					1,667
Director and Employees and Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				16,634
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																	789		2,912	267	167
Allocated Share-based Compensation Expense														36,275		298,573	$ 77,625	396,523
Fair Value Of Options				$ 1,260,437
Employee Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			2,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 105
Allocated Share-based Compensation Expense														20,433		20,433	40,867	40,867
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										1,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 102
Allocated Share-based Compensation Expense														80,425		$ 12,396	92,821	$ 24,792
Fair Value Of Options										$ 148,750
Executive Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									10,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 31.50
Fair Value Of Options														387,209			7,546
Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross									13,334
Executive Employee And Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		81,436
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 24.15
Allocated Share-based Compensation Expense														190,865			229,037
Fair Value Of Options		$ 1,832,304
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		13,573
New Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	5,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 6.93
Allocated Share-based Compensation Expense														$ 2,528			3,090
Fair Value Of Options	$ 30,341
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 9.74
Allocated Share-based Compensation Expense																	$ 363,714
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.59%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		50% of the remaining options vest on performance goals being met and 50% vest over 5 years
Employees vest equally on January 24 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 23.25
Employees vest equally on January 24 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 23.25
Executive Officer and Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights																	Of such options, 13,573 have vested at issuance and

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended	6 Months Ended	12 Months Ended
WARRANTS (Details) - $ / shares	Sep. 30, 2018	Sep. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	365,974	365,974	117,589	119,336	72,157
Number of Warrants, Issued			136,388		48,171
Number of Warrants, Exercised			(33,335)	(1,747)	(992)
Number of Warrants, Outstanding and exercisable, Ending balance	440,231	440,231	365,974	117,589	119,336
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance		$ 53.19	$ 202.50	$ 202.50	$ 202.50
Weighted-Average Exercise Price, Issued			73.02		202.50
Weighted-Average Exercise Price, Exercised			(37.50)	(120)	(120)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 44.21	44.21	$ 53.19	$ 202.50	$ 202.50
Broker [Member]
Number of Warrants, Issued			2,667
Weighted-Average Exercise Price, Issued			$ 37.50
Warrant One [Member]
Number of Warrants, Issued			559
Weighted-Average Exercise Price, Issued			$ 112.35
Warrant Two [Member]
Number of Warrants, Issued			6,275
Weighted-Average Exercise Price, Issued			$ 194
Warrant Three [Member]
Number of Warrants, Issued			13,464
Weighted-Average Exercise Price, Issued			$ 44.28
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	55.71	55.71
Warrant Four [Member]
Number of Warrants, Issued			136,388
Weighted-Average Exercise Price, Issued			$ 73.02
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 55.71	55.71
Warrant Five [Member]
Number of Warrants, Issued	67,952
Weighted-Average Exercise Price, Issued	$ 55.71
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 55.71	55.71
Warrant Six [Member]
Number of Warrants, Issued	6,305
Weighted-Average Exercise Price, Issued	$ 34.50
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 55.71	$ 55.71
Common Shares One [Member]
Number of Warrants, Issued			106,709
Weighted-Average Exercise Price, Issued			$ 9.375
Common Shares Two [Member]
Number of Warrants, Issued			15,658
Weighted-Average Exercise Price, Issued			$ 90

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	6 Months Ended
WARRANTS (Details 1) - $ / shares	Sep. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 44.21	$ 53.19	$ 202.50	$ 202.50	$ 202.50
Class of Warrant or Right, Number of Warrants	440,231
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 90
Class of Warrant or Right, Number of Warrants	15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	136,339
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	28,531
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	7,618
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	59,061
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	27,883
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 55.71
Class of Warrant or Right, Number of Warrants	27,238
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 34.50
Class of Warrant or Right, Number of Warrants	28,527
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 37.50
Class of Warrant or Right, Number of Warrants	2,667
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020
Warrant Ten [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.375
Class of Warrant or Right, Number of Warrants	64,025
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.375
Class of Warrant or Right, Number of Warrants	42,684
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	3 Months Ended	6 Months Ended			12 Months Ended
WARRANTS (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 44.21	$ 44.21	$ 53.19		$ 53.19	$ 202.50	$ 202.50	$ 202.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms		1 year 6 months 11 days			2 years 3 months 7 days
Proceeds from Warrant Exercises		$ 0		$ 1,125,038	$ 1,125,038
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					136,388		48,171
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 37.50	$ 120	$ 120
Adjustment To Additional Paid In Capital Warrant Down Feature		$ 0	$ 0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued					73.02		$ 202.50
Warrant One [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	90	$ 90	$ 37.50		$ 37.50
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					559
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 90			$ 112.35
Warrants Issued		15,658
Class of Warrant or Right Expiration Date		Mar. 31, 2023
Class of Warrant or Right Expiration years		5 years
Warrant One [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 120
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					6,275
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 194
Warrant Two [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 210
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	55.71	$ 55.71
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					13,464
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued					$ 44.28
Warrant Three [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 112.50
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	55.71	55.71
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					136,388
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued					$ 73.02
Warrant Four [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price					$ 194
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	34.50	34.50
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	37.50	37.50
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 37.50
Warrants Issued		2,667
Class of Warrant or Right Expiration Date		Jun. 27, 2020
Warrant Ten and Eleven [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	9.375	$ 9.375
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 9.375
Warrants Issued		106,709
Class of Warrant or Right Expiration Date		Mar. 31, 2023
Warrant Twelve [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 55.71
Warrant Twelve [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		73.02
Warrant Thirteen [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 34.50
Warrants Issued		6,305
Warrant Thirteen [Member] \| Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price		$ 44.28
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 55.71	$ 55.71
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	67,952
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued	$ 55.71
Retained Earnings [Member]
Class of Warrant or Right [Line Items]
Adjustment To Additional Paid In Capital Warrant Down Feature		$ (6,284)	$ (33,061)	$ (41,025)	$ (74,086)
Warrant Solicitation [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 37.50		$ 37.50

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	Mar. 06, 2018	May 17, 2017	Feb. 25, 2015	Feb. 25, 2015	Sep. 30, 2018
Description Of Contribution For Formation		Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.
Purchase Commitment, Description	On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at September 30, 2018.
Royalty on Sales,Percentage					1.00%
China JV [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%
JV Partner [Member]
Noncontrolling Interest, Ownership Percentage by Parent		75.00%
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services			1,753
Stock Transferred To Lenders			2,098
Stock to be Reimbursed to Officers			2,134
Stock Issued During Period, Value, Issued for Services			$ 241,185
Stock Issued During Period, Value, New Issues				$ 210,323

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	Sep. 30, 2018CAD ($)
Canada [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	1 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Nov. 14, 2018	Oct. 29, 2018	Feb. 13, 2015
Subsequent Event [Line Items]
Stockholders' Equity, Reverse Stock Split			the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Convertible Notes Payable	$ 2,750,000
Debt Instrument, Convertible, Terms of Conversion Feature	20% discount on a 30 day VWAP of the Company's stock price if more than $2,000,000 is raised in equity financing or matures on March 28, 2019.
Stockholders' Equity, Reverse Stock Split		the Company effected a reverse stock split and thereafter Bionik's common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split adjusted basis.